New stock news: Jiangsu Hengrui Pharmaceuticals (600276.SH) submits application to Hong Kong Stock Exchange as a leading global innovative pharmaceutical company.

According to the disclosure by the Hong Kong Stock Exchange on January 6th, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (referred to as Jiangsu Hengrui Pharmaceuticals) has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with Morgan Stanley, Citigroup, and Huatai International as joint sponsors. The prospectus shows that Jiangsu Hengrui Pharmaceuticals is an innovative pharmaceutical company rooted in China and globally leading. Since 2019, the company has been listed on the "Top 50 Global Pharmaceutical Companies" list by the US magazine "Pharm Exec" for six consecutive years. In the "Global Top 25 Pharmaceutical Company Pipeline Size" list published by Citeline in 2024, the company ranked eighth. Furthermore, based on data from Frost Sullivan, the company ranks among the top in China's pharmaceutical companies in terms of revenue from new molecular entity innovative drugs in 2023, as well as the number of new molecular entity innovative drugs in the clinical and later stages by the last feasible date. Strategically, Jiangsu Hengrui Pharmaceuticals focuses on therapeutic areas with significant unmet medical needs and substantial growth potential, including cancer, metabolism and cardiovascular diseases, immunology and respiratory diseases, and neuroscience. According to Frost Sullivan, these major therapeutic areas correspond to 57.4% of the global pharmaceutical market size in 2023, reaching $845.8 billion, with an expected compound annual growth rate of 6.4% from 2023 to 2028, exceeding the global pharmaceutical market's 5.7% compound annual growth rate over the same period. As of the last feasible date, the company has 17 marketed new molecular entity innovative drugs and over 90 new molecular entity innovative drugs in clinical and later stages of development. The company expects to maintain strong momentum in the approval and launch of innovative drugs. For example, in 2024, the company submitted eight new drug application (NDA/BLA) for innovative drugs. As evidence of the company's research and development achievements and efficiency, from 2022 to 2024, the company has published 1019 peer-reviewed articles in top international academic journals such as "The Lancet," "British Medical Journal," "JAMA," "Nature Medicine," and "Clinical Oncology," with a cumulative impact factor of approximately 7173. Financially, for the fiscal years 2022, 2023, and the nine months ended September 30th, 2023 and 2024, Jiangsu Hengrui Pharmaceuticals achieved revenues of approximately RMB 21.275 billion, RMB 22.82 billion, RMB 17.014 billion, and RMB 20.189 billion respectively, with net profits of approximately RMB 3.815 billion, RMB 4.278 billion, RMB 3.451 billion, and RMB 4.616 billion respectively.